SG10201609581TA - Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid - Google Patents
Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acidInfo
- Publication number
- SG10201609581TA SG10201609581TA SG10201609581TA SG10201609581TA SG10201609581TA SG 10201609581T A SG10201609581T A SG 10201609581TA SG 10201609581T A SG10201609581T A SG 10201609581TA SG 10201609581T A SG10201609581T A SG 10201609581TA SG 10201609581T A SG10201609581T A SG 10201609581TA
- Authority
- SG
- Singapore
- Prior art keywords
- oxadiazol
- fluorophenyl
- benzoic acid
- crystalline forms
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84732606P | 2006-09-25 | 2006-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201609581TA true SG10201609581TA (en) | 2016-12-29 |
Family
ID=39123850
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012082715A SG185979A1 (en) | 2006-09-25 | 2007-09-24 | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
SG10201609581TA SG10201609581TA (en) | 2006-09-25 | 2007-09-24 | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012082715A SG185979A1 (en) | 2006-09-25 | 2007-09-24 | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
Country Status (29)
Country | Link |
---|---|
US (10) | US7863456B2 (en) |
EP (2) | EP2559689B1 (en) |
JP (6) | JP5714228B2 (en) |
KR (1) | KR101430144B1 (en) |
CN (3) | CN102382075B (en) |
AR (2) | AR062963A1 (en) |
AU (1) | AU2007300542B2 (en) |
BR (1) | BRPI0717107A2 (en) |
CA (1) | CA2663574C (en) |
CL (1) | CL2007002743A1 (en) |
DK (1) | DK2076501T3 (en) |
ES (2) | ES2655338T3 (en) |
HK (1) | HK1207070A1 (en) |
HU (1) | HUE028503T2 (en) |
IL (1) | IL197717A (en) |
LT (1) | LTC2076501I2 (en) |
MX (2) | MX344418B (en) |
MY (1) | MY191209A (en) |
NO (1) | NO341858B1 (en) |
NZ (1) | NZ575795A (en) |
PE (3) | PE20151445A1 (en) |
PL (2) | PL2559689T3 (en) |
PT (1) | PT2076501E (en) |
SG (2) | SG185979A1 (en) |
SI (1) | SI2076501T1 (en) |
TW (2) | TWI452038B (en) |
UA (1) | UA99600C2 (en) |
WO (1) | WO2008039431A2 (en) |
ZA (1) | ZA200901949B (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05010747A (en) | 2003-04-11 | 2006-05-25 | Ptc Therapeutics Inc | 1,2,4-oxadiazole benzoic acid compounds. |
ES2390804T3 (en) * | 2005-04-08 | 2012-11-16 | Ptc Therapeutics, Inc. | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
RU2462246C2 (en) | 2006-03-30 | 2012-09-27 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Method for producing functional protein from dna having nonsense mutations, and treating associated disorders |
HUE028503T2 (en) * | 2006-09-25 | 2016-12-28 | Ptc Therapeutics Inc | Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
CL2007002923A1 (en) | 2006-10-12 | 2008-06-06 | Ptc Therapeutics Inc Soc Organ | METHOD FOR THE TREATMENT, PREVENTION OR MANAGEMENT OF A DISEASE ASSOCIATED WITH A MUTATION WITHOUT SENSE SUCH AS CANCER, DIABETES OR PULMONARY DISEASE, WHICH CONSISTS IN MANAGING A PATIENT AN EFFECTIVE AMOUNT OF ACID 3- [5- (2-FLUORO-F) -[one |
KR101713452B1 (en) | 2010-03-12 | 2017-03-07 | 오메로스 코포레이션 | Pde10 inhibitors and related compositions and methods |
WO2014153643A1 (en) * | 2013-03-26 | 2014-10-02 | The University Of British Columbia | Compositions and methods for use thereof in the treatment of aniridia |
CN105324467B (en) | 2013-04-03 | 2018-03-20 | Gfo油有限责任公司 | The method and system of acetaldehyde is produced from organic seed oil |
AU2014316682B2 (en) | 2013-09-06 | 2018-11-22 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole derivatives as immunomodulators |
CN112979575A (en) | 2014-03-06 | 2021-06-18 | Ptc医疗公司 | Pharmaceutical compositions and salts of 1,2, 4-oxadiazole benzoic acids |
NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
NZ716462A (en) | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
KR101703137B1 (en) | 2014-05-30 | 2017-02-07 | 선문대학교 산학협력단 | Glucose-attached aminoglycoside compounds, manufacturing method thereof and pharmaceutical compositions containing them as active ingredients |
CN105461650B (en) * | 2014-09-12 | 2018-04-13 | 杭州普晒医药科技有限公司 | Solvate of Yi Zhong oxadiazole compounds and preparation method thereof |
CN107427477B (en) | 2015-03-10 | 2021-11-26 | 奥瑞基尼探索技术有限公司 | 1,2, 4-oxadiazole and thiadiazole compounds as immunomodulators |
JP2018513153A (en) | 2015-04-24 | 2018-05-24 | オメロス コーポレーション | PDE10 inhibitors and related compositions and methods |
WO2017075312A1 (en) | 2015-10-30 | 2017-05-04 | Ptc Therapeutics, Inc. | Methods for treating epilepsy |
WO2017079678A1 (en) | 2015-11-04 | 2017-05-11 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
EP3442512A4 (en) * | 2016-04-15 | 2020-07-22 | The UAB Research Foundation | Methods and compounds for stimulating read-through of premature termination codons |
WO2018050706A1 (en) * | 2016-09-13 | 2018-03-22 | Marco Cipolli | Method of treatment of shwachman-diamond syndrome |
WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | Crystal forms of immunomodulators |
BR112020006669A2 (en) | 2017-10-11 | 2020-09-24 | Aurigene Discovery Technologies Limited | crystalline forms of 3-substituted 1,2,4-oxadiazole |
BR112020008537A2 (en) | 2017-11-03 | 2020-10-06 | Aurigene Discovery Technologies Limited | dual tim-3 and pd-1 pathway inhibitors |
JP7378395B2 (en) | 2017-11-06 | 2023-11-13 | オーリジーン オンコロジー リミテッド | Conjoint therapy for immunomodulation |
JP7339900B2 (en) * | 2020-02-26 | 2023-09-06 | 新 井上 | Visual field abnormality diagnostic method, visual field abnormality diagnostic device |
KR20230094597A (en) * | 2021-12-21 | 2023-06-28 | 재단법인 아산사회복지재단 | Biomarker composition for predicting susceptibility to therapeutic agent for neurofibromatosis using Ras activity and Pharmaceutical composition for preventing or treating neurofibromatosis comprising inhibitor of Ras activity |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW264475B (en) | 1991-09-20 | 1995-12-01 | Takeda Pharm Industry Co Ltd | |
US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
AU2002313633B2 (en) | 2001-06-08 | 2007-03-01 | Cytovia, Inc. | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs |
MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
WO2004001010A2 (en) * | 2002-06-21 | 2003-12-31 | Ptc Therapeutics, Inc. | METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY |
US8374966B1 (en) * | 2002-08-01 | 2013-02-12 | Oracle International Corporation | In memory streaming with disk backup and recovery of messages captured from a database redo stream |
US20040132726A1 (en) | 2002-08-09 | 2004-07-08 | Astrazeneca Ab And Nps Pharmaceuticals, Inc. | New compounds |
GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
MXPA05010747A (en) * | 2003-04-11 | 2006-05-25 | Ptc Therapeutics Inc | 1,2,4-oxadiazole benzoic acid compounds. |
US20050075375A1 (en) | 2003-05-14 | 2005-04-07 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis C virus |
CA2582885A1 (en) * | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases |
JP2008523090A (en) * | 2004-12-08 | 2008-07-03 | バイオマリン ファーマシューティカル インコーポレイテッド | Methods and compositions for the treatment of neonatal pulmonary hypertension |
ES2390804T3 (en) * | 2005-04-08 | 2012-11-16 | Ptc Therapeutics, Inc. | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
NZ575511A (en) | 2006-09-08 | 2012-02-24 | Ptc Therapeutics Inc | Processes for the preparation of 1,2,4-oxadiazole benzoic acids |
HUE028503T2 (en) * | 2006-09-25 | 2016-12-28 | Ptc Therapeutics Inc | Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
CN112979575A (en) * | 2014-03-06 | 2021-06-18 | Ptc医疗公司 | Pharmaceutical compositions and salts of 1,2, 4-oxadiazole benzoic acids |
-
2007
- 2007-09-24 HU HUE07838770A patent/HUE028503T2/en unknown
- 2007-09-24 US US11/904,005 patent/US7863456B2/en active Active
- 2007-09-24 PT PT78387701T patent/PT2076501E/en unknown
- 2007-09-24 CN CN201110283329.XA patent/CN102382075B/en active Active
- 2007-09-24 JP JP2009529270A patent/JP5714228B2/en active Active
- 2007-09-24 NZ NZ575795A patent/NZ575795A/en unknown
- 2007-09-24 SG SG2012082715A patent/SG185979A1/en unknown
- 2007-09-24 AU AU2007300542A patent/AU2007300542B2/en active Active
- 2007-09-24 ES ES12185448.3T patent/ES2655338T3/en active Active
- 2007-09-24 DK DK07838770.1T patent/DK2076501T3/en active
- 2007-09-24 CN CN201410561812.3A patent/CN104341371A/en active Pending
- 2007-09-24 AR ARP070104212A patent/AR062963A1/en not_active Application Discontinuation
- 2007-09-24 PL PL12185448T patent/PL2559689T3/en unknown
- 2007-09-24 CN CNA200780043582XA patent/CN101541770A/en active Pending
- 2007-09-24 KR KR1020097008202A patent/KR101430144B1/en active IP Right Grant
- 2007-09-24 ZA ZA200901949A patent/ZA200901949B/en unknown
- 2007-09-24 UA UAA200904012A patent/UA99600C2/en unknown
- 2007-09-24 PL PL07838770T patent/PL2076501T3/en unknown
- 2007-09-24 EP EP12185448.3A patent/EP2559689B1/en active Active
- 2007-09-24 SI SI200731750A patent/SI2076501T1/en unknown
- 2007-09-24 EP EP07838770.1A patent/EP2076501B8/en active Active
- 2007-09-24 MX MX2011007120A patent/MX344418B/en unknown
- 2007-09-24 BR BRPI0717107-2A patent/BRPI0717107A2/en not_active Application Discontinuation
- 2007-09-24 ES ES07838770.1T patent/ES2563958T3/en active Active
- 2007-09-24 MX MX2009003160A patent/MX2009003160A/en active IP Right Grant
- 2007-09-24 CL CL200702743A patent/CL2007002743A1/en unknown
- 2007-09-24 SG SG10201609581TA patent/SG10201609581TA/en unknown
- 2007-09-24 MY MYPI20091186A patent/MY191209A/en unknown
- 2007-09-24 WO PCT/US2007/020633 patent/WO2008039431A2/en active Application Filing
- 2007-09-24 CA CA2663574A patent/CA2663574C/en active Active
- 2007-09-25 PE PE2015001242A patent/PE20151445A1/en not_active Application Discontinuation
- 2007-09-25 PE PE2011001746A patent/PE20120768A1/en not_active Application Discontinuation
- 2007-09-25 PE PE2007001290A patent/PE20081225A1/en not_active Application Discontinuation
- 2007-09-26 TW TW096135785A patent/TWI452038B/en active
- 2007-09-26 TW TW103104823A patent/TWI496775B/en active
-
2009
- 2009-03-19 IL IL197717A patent/IL197717A/en active IP Right Grant
- 2009-04-16 NO NO20091488A patent/NO341858B1/en unknown
-
2010
- 2010-10-27 US US12/913,213 patent/US8394966B2/en active Active
-
2013
- 2013-02-12 US US13/764,807 patent/US8748625B2/en active Active
-
2014
- 2014-04-25 US US14/261,774 patent/US9309206B2/en active Active
-
2015
- 2015-01-09 JP JP2015003265A patent/JP6407733B2/en active Active
- 2015-08-10 HK HK15107681.2A patent/HK1207070A1/en unknown
-
2016
- 2016-03-14 US US15/068,792 patent/US10028939B2/en active Active
- 2016-04-22 LT LTPA2016012C patent/LTC2076501I2/en unknown
-
2017
- 2017-05-29 JP JP2017106030A patent/JP6495375B2/en active Active
- 2017-08-07 AR ARP170102217A patent/AR109300A2/en unknown
-
2018
- 2018-06-22 US US16/015,389 patent/US10300047B2/en active Active
-
2019
- 2019-03-06 JP JP2019040137A patent/JP2019104752A/en not_active Withdrawn
- 2019-04-10 US US16/380,218 patent/US10959988B2/en active Active
-
2020
- 2020-07-07 US US16/921,934 patent/US20200330440A1/en not_active Abandoned
-
2021
- 2021-02-24 US US17/183,342 patent/US20210330647A1/en not_active Abandoned
- 2021-05-31 JP JP2021090763A patent/JP7245868B2/en active Active
- 2021-09-30 US US17/490,725 patent/US20220023268A1/en active Pending
-
2023
- 2023-03-13 JP JP2023038770A patent/JP2023078271A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1207070A1 (en) | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]- benzoic acid 3-[5-(2-)-[124]-3-]- | |
AR118922A2 (en) | PROCESSES FOR THE PREPARATION OF 1,2,4-OXADIAZOLE BENZOIC ACIDS | |
ZA200809689B (en) | 1, 3, 4 -Oxadiazole derivatives as DGAT1 inhibitors | |
HK1158627A1 (en) | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-h- pyrrole derivatives as acid secretion inhibitors | |
HK1203959A1 (en) | Method for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl -2h-phthalazin-1-one 1-()-4-[5-[(34--4--1-) -2- | |
IL180358A0 (en) | Crystalline form iv of linezolid | |
SI2069374T1 (en) | Crystalline solvates of (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl) phenyl)-d-glucitol derivatives with alcohols as sglt2 inhibitors for the treatment of diabetes | |
HK1220686A1 (en) | Crystalline forms of 5-(2,6-di-4-morpholinyl-4-pyridmidinyl)-4- trifluoromethylpyridin-2-amine, a pik3 inhibitor pik3 5-(26--4--4-)-4--2- | |
IL207854A0 (en) | Crystal forms of 5-[3-(2,5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nit robenzene-1,2-diol | |
IL183380A0 (en) | Crystalline forms of linezolid intermediate | |
SI2132204T1 (en) | Crystalline forms of an 8-azabicyclos3.2.1coctane compound | |
IL199239A0 (en) | Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6- | |
ZA200809554B (en) | 3-(pyridin-2-yl)-[1,2,4]-triazines for use as fungicides | |
IL210924A0 (en) | A new crystalline form of 4-(5-{(ir)-1-[5-(3-chlorophenyl) isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4-triazol-3-yl)pyridine | |
CY1113938T1 (en) | PROCEDURES FOR THE PREPARATION OF 1,2,4-OXYZOZOLO Benzoic Acids | |
ZA200810321B (en) | Crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl) piperazin-1-yl]methanone phosphate | |
EP2324019A4 (en) | A crystalline form of 4-(5-{(ir)-1-[5- (3-chlorophenyl) isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4-triazol-3-yl) pyridine |